Ultra-Trace NMBA Detection Using HILIC-MS

Ultra-Trace NMBA Detection Using HILIC-MS.

When Industry Standard Methods Aren’t Sensitive Enough

Your pharmaceutical products require ultra-low nitrosamine detection limits to ensure patient safety and regulatory compliance. You’ve developed reverse-phase LC-MS methods—the industry standard for trace impurity analysis.

But for NMBA (N-Nitroso-N-methyl-4-aminobutyric acid), that standard approach repeatedly fails to achieve the sensitivity you need.

This isn’t a unique problem. NMBA is one of the most analytically challenging nitrosamines to quantify, consistently proving problematic for conventional reverse-phase methodologies. The question becomes: when the industry standard technique reaches its limits, where do you turn?

Watch: Breakthrough HILIC-MS Methodology for Ultra-Trace NMBA

In this video, Resolian analytical scientist Jenna Heath presents an alternative approach that achieves the ultra-trace detection levels that reverse-phase chromatography cannot: Hydrophilic Interaction Liquid Chromatography (HILIC) coupled with electrospray ionization mass spectrometry.

The regulatory landscape around nitrosamine impurities continues to intensify, with safety concerns driving demand for increasingly sensitive analytical methods across multiple drug classes. While numerous methodologies have been reported for nitrosamine quantification, achieving ultra-low detection for NMBA specifically has remained a persistent analytical challenge.

Jenna’s work demonstrates how switching separation mechanisms can unlock the sensitivity required.

What You’ll Learn in This Video:

  • Why reverse-phase LC-MS struggles with NMBA detection at ultra-trace levels
  • The advantages HILIC offers over conventional reverse-phase chromatography
  • How HILIC enables higher sensitivity with electrospray ionization
  • Strategic sample cleanup using anion-exchange mechanisms
  • Exploitation of NMBA’s carboxyl functional group for selective extraction
  • Method performance across liquid, gel, and cream pharmaceutical formulations
  • Quantitative detection achievement: 0.8 ng/mL

The methodology combines smart separation chemistry with targeted sample preparation. By utilizing Waters Oasis Max cartridges containing anion-exchange groups alongside standard reverse-phase sorbent, the method achieves high selectivity for NMBA as an acidic compound. At high pH, the compound locks to the sorbent via ion-exchange; at low pH, it elutes as a neutral species—providing clean, selective extraction.

Download Poster

Download a copy of the poster discussed here.

Why HILIC Makes the Difference

Hydrophilic Interaction Liquid Chromatography offers several fundamental advantages for challenging analytes like NMBA:

  • Alternative selectivity compared to reverse-phase, enabling separation where conventional methods struggle
  • Enhanced sensitivity when coupled with electrospray ionization MS
  • Lower back pressure allowing higher flow rates and potentially faster methods
  • Better retention for polar compounds that elute too quickly on reverse-phase

These aren’t merely incremental improvements—they represent a different separation mechanism that opens analytical possibilities when conventional approaches reach their limits.

Meeting Ultra-Trace Requirements

Achieving 0.8 ng/mL quantitative detection represents the kind of ultra-trace capability that pharmaceutical companies increasingly need to demonstrate compliance with evolving nitrosamine guidance. This level of sensitivity enables:

  • Confident testing against stringent regulatory limits
  • Analysis across diverse formulation types
  • Method validation at levels previously unachievable with reverse-phase
  • Reduced uncertainty in safety assessments

Expert Problem-Solving for Challenging Analyses

Not every analytical challenge yields to standard techniques. Some require re-examining fundamental separation mechanisms and exploring alternative approaches.

Resolian’s analytical sciences department specializes in developing methods for analytically challenging compounds—the impurities that don’t respond to conventional techniques, the detection limits that seem unreachable with standard equipment, the matrix effects that complicate straightforward analyses.

Our team combines deep chromatographic expertise with strategic problem-solving to develop robust, validated methods that achieve what’s needed, even when initial approaches fall short.

Whether you’re struggling with specific nitrosamine detection, facing ultra-low limit requirements, or dealing with challenging matrices, we bring the technical depth and creative methodology development that turns analytical obstacles into solutions.

Ready to discuss your challenging nitrosamine analysis?

Contact our analytical sciences team to explore how advanced separation techniques can address your specific detection requirements.

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.